Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Real-World Blood Counts in Patients Treated with Venetoclax for Relapsed or Refractory CLL/SLL

Laura Samples, Sirin Khajaviyan, Sara Keshmiri, Ryan S. Basom, Ryan C Lynch, Vikram Raghunathan, Mengyang Di, Mehrdad Shakib-Azar, Christine Crider, Margie Fredericks, Christina Poh, Stephanie Louie, Stephen D. Smith, Brian G. Till, Ajay K. Gopal, Chaitra S. Ujjani, Mazyar Shadman

Blood (2024) 144 (Supplement 1): 6785.

https://doi.org/10.1182/blood-2024-211971

Published: 2024

Journal Articles

Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia

Christina Poh, Xueyan Chen, Jenna M. Voutsinas, Edus H. Warren, Mazyar Shadman, Ryan C. Lynch, Brian G. Till, Chaitra S. Ujjani, Mengyang Di, Vikram Raghunathan, Stephen D. Smith, Qian Vicky Wu, Sindhu Cherian, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 3069.

https://doi.org/10.1182/blood-2024-205892

Published: 2024

Journal Articles

Evaluating Reasons for Differences in Real-World (RW) Clinical Outcomes Among Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) on Covalent BTK Inhibitors (cBTKis)

Tycel Phillips, Mengyang Di, Taavy Miller, Jingru Wang, Amy Pierre, Gregory A. Maglinte, Erlene Kuizon Seymour, Yucai Wang

Blood (2024) 144 (Supplement 1): 3732.

https://doi.org/10.1182/blood-2024-208063

Published: 2024

Journal Articles

Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

Blood (2024) 144 (Supplement 1): 4431.

https://doi.org/10.1182/blood-2024-200719

Published: 2024

Journal Articles

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Blood (2024) 144 (Supplement 1): 6451.

https://doi.org/10.1182/blood-2024-194844

Published: 2024

Journal Articles

Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

Carrie I Ho, Neena Kennedy, Mengyang Di, Ajay K. Gopal, Ryan C Lynch, Christina Poh, Vikram Raghunathan, Heather Rasmussen, Mazyar Shadman, Brian G. Till, Chaitra S. Ujjani, Stephen D. Smith

Blood (2024) 144 (Supplement 1): 783.

https://doi.org/10.1182/blood-2024-208269

Published: 2024

Journal Articles

A Pilot Trial of Low Dose-Mosunetuzumab for Low-Tumor Burden Indolent B-Cell Lymphoma: Trial in Progress

Carrie I Ho, Mengyang Di, Ryan C Lynch, Christina Poh, Vikram Raghunathan, Mazyar Shadman, Stephen D. Smith, Brian G. Till, Paul S Martin, Chaitra S. Ujjani, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 1661.2.

https://doi.org/10.1182/blood-2024-204154

Published: 2024

Journal Articles

Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial

Jennifer J. Huang, Laura Samples, Margie Fredericks, Stephanie Louie, Ramya Pulluru, Christine Crider, Mehrdad Shakib-Azar, Neena Kennedy, Vikram Raghunathan, Christina Poh, Mengyang Di, Stephen D. Smith, Brian G. Till, Ajay K. Gopal, Chaitra S. Ujjani, Ryan C. Lynch, Mazyar Shadman

Blood (2024) 144 (Supplement 1): 4634.2.

https://doi.org/10.1182/blood-2024-204491

Published: 2024

Journal Articles

Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas

Christina Poh, Jenna M. Voutsinas, Ivan Huang, Edus H. Warren, Caitlin A. Crimp, Mazyar Shadman, Ryan C. Lynch, Brian G. Till, Chaitra S. Ujjani, Mengyang Di, Vikram Raghunathan, Stephen D. Smith, Qian Vicky Wu, Michi M. Shinohara, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 1684.

https://doi.org/10.1182/blood-2024-194018

Published: 2024

Journal Articles

Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma

Mengyang Di, Carrie I Ho, Stephen D. Smith, Mazyar Shadman, Chaitra S. Ujjani, Ryan C. Lynch, Christina Poh, Vikram Raghunathan, Brian G. Till, Edus H. Warren, Ajay K. Gopal, Stephanie J. Lee

Blood (2024) 144 (Supplement 1): 5116.

https://doi.org/10.1182/blood-2024-201827

Published: 2024

Journal Articles

Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience

Ramzi Hamouche, Francine M. Foss, Sayeef Mirza, Mengyang Di, Iris Isufi, Noffar Bar, Lohith Gowda, Sarah Perreault, Kenneth Roberts, Stuart Seropian, Tarsheen Sethi

Blood (2023) 142 (Supplement 1): 2172.

https://doi.org/10.1182/blood-2023-189414

Published: 2023

Journal Articles

Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based Analysis

Mengyang Di, Jessica B Long, Shalin K. Kothari, Tarsheen Sethi, Amer M. Zeidan, Nikolai A. Podoltsev, Rory Michael Shallis, Rong Wang, Jessica M. Stempel, Xiaomei Ma, Scott F. Huntington

Blood (2022) 140 (Supplement 1): 10904–10906.

https://doi.org/10.1182/blood-2022-164959

Published: 2022

Journal Articles

Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis

Mengyang Di, Jessica B Long, Iris Isufi, Francine M. Foss, Stuart Seropian, Cary P Gross, Scott F. Huntington

Blood (2022) 140 (Supplement 1): 10818–10819.

https://doi.org/10.1182/blood-2022-164915

Published: 2022

Journal Articles

Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib

Jessica M. Stempel, Rong Wang, Rory Michael Shallis, Scott F. Huntington, Amer M. Zeidan, Natalia Neparidze, Mengyang Di, Xiaomei Ma, Nikolai A. Podoltsev

Blood (2022) 140 (Supplement 1): 11004–11006.

https://doi.org/10.1182/blood-2022-165156

Published: 2022

Journal Articles

Contemporary "Real World" Molecular Testing and Tyrosine Kinase Inhibitor Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United States

Rory M. Shallis, Rong Wang, Amer M. Zeidan, Scott F. Huntington, Natalia Neparidze, Mengyang Di, Xiaomei Ma, Nikolai Podoltsev

Blood (2021) 138 (Supplement 1): 282.

https://doi.org/10.1182/blood-2021-151066

Published: 2021

Journal Articles

Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based Analysis

Mengyang Di, Can Cui, Shalin K. Kothari, Amer M. Zeidan, Nikolai Podoltsev, Natalia Neparidze, Rory M. Shallis, Rong Wang, Xiaomei Ma, Scott F. Huntington

Blood (2021) 138 (Supplement 1): 182.

https://doi.org/10.1182/blood-2021-146417

Published: 2021

Journal Articles

Functional Status and Therapy for Nursing Home Residents with Diffuse Large B-Cell Lymphoma: A Population-Based Study

Mengyang Di, Adam J. Olszewski, Tamra Keeney, Emmanuelle Belanger, Orestis A. Panagiotou

Blood (2021) 138 (Supplement 1): 1918.

https://doi.org/10.1182/blood-2021-146498

Published: 2021

Journal Articles

Functional Status and Therapy for Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Population-Based Study

Mengyang Di, MD PhD, Tamra Keeney, DPT, PhD, Emmanuelle Belanger, PhD, Orestis A. Panagiotou, MD PhD, Adam J Olszewski, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137714

Published: 2020

Journal Articles

Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma

Kishan Patel, BS, Terri L. Parker, MD, Mengyang Di, MD PhD, Noffar Bar, MD, Scott F. Huntington, MD MPH, Smith Giri, MDMS

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-141972

Published: 2020

Journal Articles

Exposure to Ibritumomab Tiuxetan and Incidence of Treatment-Related Myeloid Neoplasms Among Older Patients with B-Cell Lymphoma: A Population-Based Study

Mengyang Di, MD PhD, Thomas A Ollila, MD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 3477.

https://doi.org/10.1182/blood-2019-121959

Published: 2019

NARROW

Real-World Blood Counts in Patients Treated with Venetoclax for Relapsed or Refractory CLL/SLL

Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia

Evaluating Reasons for Differences in Real-World (RW) Clinical Outcomes Among Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) on Covalent BTK Inhibitors (cBTKis)

Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

A Pilot Trial of Low Dose-Mosunetuzumab for Low-Tumor Burden Indolent B-Cell Lymphoma: Trial in Progress

Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial

Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas

Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma

Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience

Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based Analysis

Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis

Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib

Contemporary "Real World" Molecular Testing and Tyrosine Kinase Inhibitor Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United States

Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based Analysis

Functional Status and Therapy for Nursing Home Residents with Diffuse Large B-Cell Lymphoma: A Population-Based Study

Functional Status and Therapy for Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Population-Based Study

Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma

Exposure to Ibritumomab Tiuxetan and Incidence of Treatment-Related Myeloid Neoplasms Among Older Patients with B-Cell Lymphoma: A Population-Based Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only